文献速递膀胱癌与上尿路尿路上皮癌

基于生物标志物筛选肌层浸润性膀胱癌新辅助化疗的成本效果模型

Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
PubMed 文献 · BJU Int · 2018-04-24

本研究采用决策分析模型,评估基于生物标志物筛选肌层浸润性膀胱癌患者接受新辅助化疗的成本效果。

要点

  • DNA修复基因面板筛选新辅助化疗最具成本效果
  • 该策略下38%患者接受新辅助化疗,约为当前两倍
  • 较单独根治性膀胱切除术提高平均总生存5.2个月

核心结论

  • 基于生物标志物筛选肌层浸润性膀胱癌患者接受新辅助化疗比未筛选新辅助化疗或单独根治性膀胱切除术更具成本效果。

研究设计与样本

  • 决策分析模型,数据来自局部晚期肌层浸润性膀胱癌接受根治性膀胱切除术的最新临床研究。

主要发现

  • 该策略下38%患者接受新辅助化疗,约为当前接受新辅助化疗患者数量的两倍。
  • 较单独根治性膀胱切除术提高平均总生存5.2个月,较假设所有患者接受新辅助化疗提高1.6个月,较当前新辅助化疗使用估计提高4.4个月。

关键数值与推荐

  • 评估了三种生物标志物:DNA修复基因面板(ATM、RB1、FANCC)、ERCC2和RNA亚型。
  • 比较策略包括单独根治性膀胱切除术、未筛选新辅助化疗加根治性膀胱切除术、基于三种生物标志物的新辅助化疗。

临床怎么用

  • 生物标志物策略可用于筛选肌层浸润性膀胱癌患者接受新辅助化疗,较未筛选使用或单独手术更具成本效果。
  • 随着更多数据可用,该模型可作为将生物标志物纳入临床决策的基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To model the cost-effectiveness of a biomarker-based approach to select patients for neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS: We obtained data from the most recent clinical studies on patients with locally advanced MIBC treated by RC, including stage distributions, overall survival (OS) estimates, associated costs, and utilisation/response to NAC. Additionally, we estimated the putative efficacy of three biomarkers to select patients for NAC: DNA-repair gene panel [ataxia telangiectasia mutated (ATM), retinoblastoma 1 (RB1), and Fanconi anaemia complementation group C (FANCC)], excision repair cross-complementation group 2 (ERCC2), and ribonucleic acid (RNA) subtypes. A decision analysis model was developed to evaluate the cost-effectiveness of biomarker-based approaches to select patients with MIBC for NAC. Comparison of cost-effectiveness included RC alone, unselected NAC plus RC, and NAC based on the three aforementioned biomarkers. RESULTS: The DNA-repair gene panel-based approach to NAC was the most cost-effective strategy (mean OS of 3.14 years, $31 482/life year). Under this approach, 38% would undergo NAC, about twice the number of patients who are currently receiving NAC for MIBC. Such an approach would improve mean OS by 5.2, 1.6, and 4.4 months compared to RC alone, a hypothetical scenario where all patients received NAC, and compared to current estimates of NAC utilisation, respectively. CONCLUSIONS: A biomarker-based strategy to identify patients with MIBC who should undergo NAC was more cost-effective than unselected use of NAC or RC alone. As further data becomes available, such a model may serve as a basis for incorporating biomarkers into clinical decision making.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lotan Y, Woldu SL, Sanli O, et al. Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. BJU Int. 2018. PMID: 29603871. doi:10.1111/bju.14220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。